[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse LLGL2

Summary
SymbolLLGL2
Namelethal giant larvae homolog 2 (Drosophila)
Aliases Hugl-2; lethal giant larvae (Drosophila) homolog 2; human giant larvae homolog; Lethal(2) giant larvae prote ......
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Note=Localized in the perinuclear structure and faintly at the cell-cell contacts sites in the interphase. Localized at the cell periphery during metaphase. Cortical localization in mitotic cells. Found in the lateral region of polarized epithelial cells.
Domain PF08366 LLGL2
PF00400 WD domain
Function

Part of a complex with GPSM2/LGN, PRKCI/aPKC and PARD6B/Par-6, which may ensure the correct organization and orientation of bipolar spindles for normal cell division. This complex plays roles in the initial phase of the establishment of epithelial cell polarity.

> Gene Ontology
 
Biological Process GO:0000226 microtubule cytoskeleton organization
GO:0006887 exocytosis
GO:0007163 establishment or maintenance of cell polarity
GO:0007219 Notch signaling pathway
GO:0008593 regulation of Notch signaling pathway
GO:0009306 protein secretion
GO:0030010 establishment of cell polarity
GO:0030865 cortical cytoskeleton organization
GO:0030866 cortical actin cytoskeleton organization
GO:0032878 regulation of establishment or maintenance of cell polarity
GO:0050708 regulation of protein secretion
GO:0051293 establishment of spindle localization
GO:0051294 establishment of spindle orientation
GO:0051640 organelle localization
GO:0051653 spindle localization
GO:0051656 establishment of organelle localization
Molecular Function GO:0005096 GTPase activator activity
GO:0008047 enzyme activator activity
GO:0017016 Ras GTPase binding
GO:0017137 Rab GTPase binding
GO:0030165 PDZ domain binding
GO:0030695 GTPase regulator activity
GO:0031267 small GTPase binding
GO:0051020 GTPase binding
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0005938 cell cortex
GO:0015629 actin cytoskeleton
GO:0030863 cortical cytoskeleton
GO:0030864 cortical actin cytoskeleton
GO:0044448 cell cortex part
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04390 Hippo signaling pathway
hsa04530 Tight junction
Reactome -
Summary
SymbolLLGL2
Namelethal giant larvae homolog 2 (Drosophila)
Aliases Hugl-2; lethal giant larvae (Drosophila) homolog 2; human giant larvae homolog; Lethal(2) giant larvae prote ......
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LLGL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolLLGL2
Namelethal giant larvae homolog 2 (Drosophila)
Aliases Hugl-2; lethal giant larvae (Drosophila) homolog 2; human giant larvae homolog; Lethal(2) giant larvae prote ......
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LLGL2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLLGL2
Namelethal giant larvae homolog 2 (Drosophila)
Aliases Hugl-2; lethal giant larvae (Drosophila) homolog 2; human giant larvae homolog; Lethal(2) giant larvae prote ......
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LLGL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6670.117
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1110.921
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.2460.0935
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.3940.0357
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.1220.622
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.7480.573
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3770.411
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7170.37
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1320.894
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3690.806
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1290.95
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0910.503
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LLGL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLLGL2
Namelethal giant larvae homolog 2 (Drosophila)
Aliases Hugl-2; lethal giant larvae (Drosophila) homolog 2; human giant larvae homolog; Lethal(2) giant larvae prote ......
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LLGL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLLGL2
Namelethal giant larvae homolog 2 (Drosophila)
Aliases Hugl-2; lethal giant larvae (Drosophila) homolog 2; human giant larvae homolog; Lethal(2) giant larvae prote ......
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LLGL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LLGL2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLLGL2
Namelethal giant larvae homolog 2 (Drosophila)
Aliases Hugl-2; lethal giant larvae (Drosophila) homolog 2; human giant larvae homolog; Lethal(2) giant larvae prote ......
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LLGL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLLGL2
Namelethal giant larvae homolog 2 (Drosophila)
Aliases Hugl-2; lethal giant larvae (Drosophila) homolog 2; human giant larvae homolog; Lethal(2) giant larvae prote ......
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LLGL2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLLGL2
Namelethal giant larvae homolog 2 (Drosophila)
Aliases Hugl-2; lethal giant larvae (Drosophila) homolog 2; human giant larvae homolog; Lethal(2) giant larvae prote ......
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LLGL2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLLGL2
Namelethal giant larvae homolog 2 (Drosophila)
Aliases Hugl-2; lethal giant larvae (Drosophila) homolog 2; human giant larvae homolog; Lethal(2) giant larvae prote ......
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LLGL2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.